Forte Biosciences, Inc. (FBRX) News
Filter FBRX News Items
FBRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest FBRX News From Around the Web
Below are the latest news stories about FORTE BIOSCIENCES INC that investors may wish to consider to help them evaluate FBRX as an investment opportunity.
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesDALLAS, December 01, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. |
Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business UpdateDALLAS, November 13, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2023 results and provided a business update. |
ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company’s Upcoming Annual MeetingNEW YORK, September 14, 2023--Camac Partners, LLC ("Camac") and ATG Capital Management, LLC ("ATG") (together with the other participants in their solicitation, the "Concerned Stockholders," the "Group" or "we"), which collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (Nasdaq: FBRX) ("Forte" or the "Company"), today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co., LLC ("Gla |
Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s BoardroomNEW YORK, September 06, 2023--Camac Partners, LLC ("Camac") and ATG Capital Management, LLC ("ATG") (together with the other participants in their solicitation, the "Concerned Stockholders," the "Group" or "we") collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (Nasdaq: FBRX) ("Forte" or the "Company"). Today, the Group and its independent director candidates – Michael Hacke and Chris McIntyre – responded to misrepresentations and distortions included |
Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to StockholdersNEW YORK, August 25, 2023--Camac Partners, LLC ("Camac") and ATG Capital Management, LLC ("ATG") (together with the other participants in their solicitation, the "Concerned Stockholders," the "Group" or "we"), who collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (Nasdaq: FBRX) ("Forte" or the "Company"), today announced that they have filed a definitive proxy statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with Fo |
Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business UpdateDALLAS, August 14, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-detailed diseases, today announced second quarter 2023 results and provided a business update. |
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102DALLAS, August 01, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced key R&D updates for FB-102 and the closing of financing to support the advancement of FB-102. |
Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of DirectorsDr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermed |
Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business UpdateDALLAS, May 15, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2023 results and provided a business update. |
Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business UpdateDALLAS, March 31, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced full year 2022 results and provided a business update. |